Lonasen (Sumitomo Dainippon/Nitto Denko) Drug Overview 2018 - ResearchAndMarkets.com

DUBLIN--()--The "Drug Overview: Lonasen" report has been added to ResearchAndMarkets.com's offering.

Lonasen (Sumitomo Dainippon/Nitto Denko) contains blonanserin, a dopamine D2 and serotonin 5-HT2 receptor antagonist. The drug possesses a stronger blocking action to D2 receptors than to 5-HT2 receptors, and is structurally unrelated to typical antipsychotics or to newer agents such as risperidone. Given its weak adrenaline receptor blocking, the drug typically has minimal sedative and hypotensive effects.

Through Sumitomo Dainippon's expertise in Japan, the company has grown its brand Lonasen into a major product in the country's schizophrenia market. Clinical trial data indicated that Lonasen's efficacy extended to negative symptoms in schizophrenia, which significantly distinguishes it from other atypical antipsychotics and crucially addresses an unmet need. However, generic competition poses the greatest threat to Lonasen's success, and the drug's impending loss of exclusivity in April 2018 will significantly erode its market share.

Key Topics Covered:

  1. Drug Overview
  2. Product Profiles
  3. Lonasen: Schizophrenia

List of Figures

Figure 1: Lonasen for schizophrenia - SWOT analysis

Figure 2: Drug assessment summary of Lonasen for schizophrenia

Figure 3: Drug assessment summary of Lonasen for schizophrenia

Figure 4: Lonasen sales for schizophrenia in Japan, 2017-26

List of Tables

Table 1: Lonasen drug profile

Table 2: Lonasen pivotal trial data in schizophrenia

Table 3: Lonasen transdermal patch trial data in schizophrenia

Table 4: Lonasen ongoing trials in schizophrenia

Table 5: Lonasen sales for schizophrenia in Japan ($m), 2017-26

For more information about this report visit https://www.researchandmarkets.com/research/mr9zk4/lonasen_sumitomo?w=4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Schizophrenia Drugs